Background: Our aim was to detect differences in protein expression profiles of cerebrospinal fluid (CSF) from pediatric patients with and without brain tumors. Methods: We used surface-enhanced laser desorption/ ionization time-of-flight (SELDI-TOF) mass spectrometry and Q10 ProteinChip arrays to compare protein expression profiles of CSF from 32 pediatric brain tumor patients and 70 pediatric control patients. A protein with high discriminatory power was isolated and identified by subsequent anion-exchange and reversed-phase fractionation, gel electrophoresis, and mass spectrometry. The identity of the protein was confirmed by Western blotting and immunohistochemistry. Results: Of the 247 detected protein peak clusters, 123 were differentially expressed between brain tumor and control patients with a false discovery rate of 1%. Double-loop classification analysis gave a mean prediction accuracy of 88% in discriminating brain tumor patients from control patients. From the 123 clusters, a highly overexpressed protein peak cluster in CSF from brain tumor patients was selected for further analysis and identified as apolipoprotein A-II. Apolipoprotein A-II expression in CSF was correlated with the CSF albumin concentration, suggesting that the overexpres-
spectrometry is based on 2 techniques: chromatography and mass spectrometry (2 ) . Proteins from complex protein mixtures are retained on specific chromatographic surfaces and subsequently analyzed by a linear TOF mass spectrometer to detect differences in protein expression profiles between groups of patients. The SELDI approach has recently been used successfully to identify biomarkers in biological fluids in various malignancies (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) .
It has been shown that disease-related proteins can be detected in cerebrospinal fluid (CSF) of patients with a primary brain tumor by 2-dimensional gel electrophoresis (16 ) and in Alzheimer patients by SELDI-TOF mass spectrometry (17 ) . The objective of this study was to determine whether protein expression profiles obtained by SELDI-TOF mass spectrometry of CSF can be used to distinguish pediatric brain tumor patients from control patients.
Materials and Methods study population and samples
A total of 32 lumbar CSF samples from newly diagnosed and untreated pediatric brain tumor patients (17 males and 15 females; median age, 7.2 years) and 70 pediatric control patients (39 males and 31 females; median age, 8.5 years) were analyzed in this study. All CSF samples were collected at the Erasmus MC-University Medical Center-Sophia Children's Hospital in Rotterdam, The Netherlands under uniform and standardized conditions. The brain tumor group consisted of 16 patients with medulloblastoma and 16 brain tumor patients with other histologic subtypes (high-grade glioma, n ϭ 7; atypical rhabdoid tumor, n ϭ 2; pilocytic astrocytoma, n ϭ 2; plexus carcinoma, n ϭ 2; anaplastic ependymoma, n ϭ 2; germ cell tumor, n ϭ 1), which will be referred to as "other tumors".
The 70 lumbar control CSF samples were obtained from pediatric patients 1 year after the end of treatment for acute lymphoblastic leukemia (n ϭ 47), pediatric patients without a malignancy (infection, n ϭ 6; hematologic disease, n ϭ 4; autoimmune disease, n ϭ 2, idiopathic intracranial hypertension, n ϭ 1) and pediatric patients with a malignancy outside the central nervous system (Hodgkin disease, n ϭ 6; neuroblastoma, n ϭ 4). Each patient or the patient's parents gave informed consent before enrollment.
Cytologic analysis of the CSF samples showed malignant cells in 10 medulloblastoma CSF samples. CSF from patients with other tumors and from control patients did not show any cytologic abnormalities.
sample preparation
All CSF samples were immediately centrifuged at 250g for 5 min to remove cellular debris, and cytospins were made to evaluate cytology. Supernatants were aliquoted and stored at Ϫ80°C until analysis. Only CSF samples without macroscopic blood contamination were included in the study.
Before SELDI protein profiling, the protein concentration of the CSF samples was determined by the bicinchoninic acid protein assay (Pierce).
seldi protein profiling

Q10 ProteinChip
® arrays (strong anion-exchange chromatographic surface; Ciphergen Biosystems Inc.) were equilibrated with 50 mmol/L Tris (pH 8.5) containing 1 mL/L Triton (binding buffer). Crude CSF samples, each containing 5 g of protein, were loaded on the arrays in duplicate together with binding buffer and incubated for 1 h at room temperature. Arrays were washed sequentially with 50 mmol/L Tris (pH 8.5) containing 1 mL/L Triton, 50 mmol/L Tris (pH 8.5), and deionized water. After the arrays were air-dried at room temperature, energy-absorbing matrix sinapinic acid in an aqueous solution containing 500 mL/L acetonitrile and 5 mL/L trifluoroacetic acid was added to each spot. Mass analysis of the bound proteins was performed with a PBS IIc instrument (Ciphergen) in positive operating mode. Mass spectra were collected by the accumulation of 65 laser shots at a laser intensity of 175 and a detector sensitivity of 8. The highest mass to acquire was set at m/z 200 000 with an optimization range between m/z 2000 and 30 000. The instrument was calibrated by use of Protein Calibration Standard I (Bruker Daltonics). Peak detection and clustering were performed with the ProteinChip Biomarker Wizard TM module embedded in the ProteinChip software, Ver. 3.1 (Ciphergen).
All spectra were compiled, aligned to a common calibrant, and normalized to the total ion current. The Biomarker Wizard automatically detected peaks with a signal-to-noise ratio Ͼ5. Subsequently, peaks were clustered by use of a 0.3% mass window and a second-pass peak selection with a signal-to-noise ratio Ͼ2. The part of the spectrum with m/z values Ͻ2000 was not used for analysis because the signal for the energy-absorbing matrix generally interferes with peak detection in this area.
We used the nonparametric Mann-Whitney U-test implemented in the Biomarker Wizard software to statistically compare differences in intensity data for the various protein peak clusters after normalization between patients with brain tumor and control patients. We corrected for multiple testing errors by applying the false discovery rate (FDR) described by Benjamini and Hochberg (18 ) . We used a FDR of 1%, which means that 99% of the selected protein peaks are expected to be true positive and not found by chance. We used the 123 protein peak clusters differentially expressed between brain tumor and control patients to perform a double-loop classification analysis with Biomarker Patterns TM software (Ciphergen). Biomarker Patterns software is a tool for tree-structured data analysis, in which classification and regression trees (CART) methodology (19 ) is implemented. The data were randomly split into a training set (two thirds of the data; n control ϭ 47; n brain tumor ϭ 21) and a test set (one third of the data; n control ϭ 23; n brain tumor ϭ 11). The training set was used to generate the optimal classification tree in the Biomarker Patterns Software by use of a 10-fold internal cross-validation procedure. The optimal classification tree was tested for accuracy by the test set. The prediction accuracy was calculated as the ratio of correctly classified brain tumor samples to the total number of brain tumor samples. Specificity was calculated as the ratio of correctly classified control samples to the total number of control samples. This procedure was repeated 3 times with randomly chosen training (two thirds of samples) and test (one third of samples) sets. Mean values of prediction accuracy and specificity of the 3 repeated classification analyses are reported.
purification and identification of differentially expressed proteins (normal-phase chromatographic surface) ProteinChip arrays] were subjected to nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 16% Tris-glycine gels. The gel was stained with Coomassie blue (Invitrogen), and gel bands were cut. After destaining in 500 mL/L acetonitrile-500 mL/L 50 mmol/L ammonium bicarbonate and dehydration in acetonitrile, bands were dried in a SpeedVac. Proteins were passively eluted out of the gel bands by rehydration in 450 mL/L formic acid-300 mL/L acetonitrile-100 mL/L isopropanol and sonication for 3.5 h at room temperature. The extracts containing the markers (tested on NP20 arrays) were dried in a SpeedVac, resuspended in 20 g/L modified trypsin (Roche Applied Science) dissolved in 100 mmol/L ammonium bicarbonate-100 mL/L acetonitrile, and incubated for 4 h at 37°C. Peptide mass spectra obtained in the ProteinChip System Series 4000 instrument (Ciphergen) were used for peptide mass fingerprinting (ProFound database). Tandem mass spectrometry (MS/MS) of selected peptides was done with a Micromass Q-TOFII equipped with a PCI 1000 ProteinChip Tandem MS Interface (Ciphergen).
western blots CSF samples (9.7 g of protein) were subjected to nonreducing SDS-PAGE on 15% Tris-glycine gels. After proteins were transferred to a nitrocellulose membrane at 140 V for 90 min at 4°C in a wet transfer system (Bio-Rad) and blocking with block buffer [50 g/L nonfat milk in 0.01 mmol/L phosphate-buffered saline (pH 7.4) containing 2 mL/L Tween 20] for 30 min, the membrane was incubated overnight at 4°C with mouse monoclonal antibodies against apolipoprotein A-II (APO-A-II; Biodesign International) diluted (1:400) in blocking buffer. The membrane was washed with 2 mL/L Tween 20 in 0.01 mmol/L phosphate-buffered saline (pH 7.4) and incubated for 1 h at room temperature with antimouse IgG-horseradish peroxidase conjugate (DakoCytomation) diluted (1:500) in blocking buffer containing 20 mL/L pooled human serum. Detection solution (SuperSignal West Femto Maximum Sensitivity Substrate; Pierce) was prepared according to the manufacturer's instructions. Chemiluminescence was measured with the Syngene chemigenius.
csf/blood albumin quotient
The albumin concentration was analyzed in paired CSF and EDTA-plasma samples from 22 brain tumor patients by an immunochemical albumin assay on the Immage 800 system (Beckman Coulter). The CSF/blood albumin quotient (Q alb ) was calculated and used as an estimation of the integrity of the blood-brain barrier. In 20 CSF samples from control patients, the albumin concentration was determined by the same assay. As no paired plasma samples for these control patients were available, we determined the plasma albumin concentration reference range with this assay in a separate set of 27 healthy pediatric control patients (median, 32.3 g/L; range, 11.3-41.4 g/L). The Q alb in the control patients was then calculated by use of the median plasma albumin concentration from the separate control set.
immunohistochemistry
We sectioned formalin-fixed, paraffin-embedded tissues from the medulloblastoma, ependymoma, high-grade glioma, control cerebellum, and prostate carcinoma into 4-m-thick sections and stained them with hematoxylin and eosin for histologic examination. Prostate carcinoma tissue sections showed specific staining after incubation with the primary antibodies and were used as positive control [also described by Malik et al. (6 ) ]. Tissue sections incubated with only the secondary antibody were used as negative controls. Sections were deparaffinized and rehydrated through a graded xylene-ethanol series. Antigen retrieval, achieved by boiling the slides for 5 min in 0.01 mol/L citric acid (pH 6.0), was followed by a 30-min incubation in 30 mL/L hydrogen peroxide in 0.01 mmol/L phosphate-buffered saline (pH 7.4) to inhibit endogenous peroxidases. We then added 30 mL/L goat serum or 30 mL/L horse serum (Vector Laboratories) as a protein block for the monoclonal and polyclonal antibodies, respectively. Tissue sections were incubated with either a monoclonal 
Results reproducibility
The CV for the protein peak intensities obtained by SELDI-TOF mass spectrometry was determined on 12 protein peak clusters present in both a brain tumor and a control sample, which were measured in 8 independent experiments. The CV of the peak intensities for the 12 peak clusters ranged from 6% to 24% and did not differ statistically between the brain tumor and control CSF sample.
seldi mass spectrometry
Mass spectrometric analysis of the proteins from the CSF of brain tumor and control patients that were bound to the affinity tags of the Q10 ProteinChip arrays (Ciphergen) revealed 247 protein peak clusters between m/z 2000 and 200 000. When we used an FDR of 1%, 123 protein peak clusters were significantly different between brain tumor and control patients. These protein peak clusters were used in a double-loop classification analysis. The most accurate classification models had a mean prediction accuracy of 88% (range, 82%-100%) and a mean specificity of 88% (range, 78%-96%) in discriminating CSF of brain tumor patients from CSF of control patients.
None of the 247 detected protein peak clusters was found to be differentially expressed between the different histologic brain tumor subtypes or between medulloblastoma patients with and without CSF cytologic abnormalities.
identification of protein markers
From the 123 differentially expressed protein peak clusters, we selected a protein peak cluster at M r 17 000, consisting of an m/z 17 248 and an m/z 17 369 protein peak, that was highly abundant in brain tumor patients but virtually absent in control patients (Fig. 1) . To identify this protein cluster, we subjected CSF from a brain tumor patient sequentially to 3 fractionation methods. On anionexchange Q ceramic HyperD F columns, the m/z 17 000 protein cluster eluted in the pH 5.0 and pH 4.0 fractions ( Fig. 2A) . When the of the pooled pH 4.0 and pH 5.0 fractions were further fractionated by use of RPC beads, the of the m/z 17 000 peaks eluted in the 500 mL/L acetonitrile wash fraction (Fig. 2B) , which was subsequently subjected to nonreducing SDS-PAGE on 16% Tris-glycine gels (Fig. 2C) . Nine gel bands were cut from the gel (Fig. 2C) and processed for passive elution, which revealed that the m/z 17 000 protein cluster was present in gel band 7 (Fig. 2D) .
Subsequent peptide mass fingerprinting (ProFound) after tryptic digestion of the passive elution from band 7 gave a significant hit (Z ϭ 2.39) for APO A-II (sequence coverage, 88%). MS/MS analysis of 3 peptide peaks in the peptide mass spectrum (Fig. 2E , peaks indicated by ‫)ء‬ confirmed the identification of APO A-II [also see supplementary information I-III (in the Data Supplement that accompanies the online version of this article at http:// www.clinchem.org/content/vol52/issue8/) for MS/MS data on the 3 peptide peaks].
Western blot analysis revealed staining of 2 protein bands at approximately M r 17 000 and M r 34 000 by anti-APO A-II antibody. These proteins were abundantly present in CSF of brain tumor patients compared with control cases (Fig. 3) . This confirmed the identification and differential expression of APO A-II in CSF of control and brain tumor patients.
disrupted blood-brain barrier
The observed increase in APO A-II in CSF of brain tumor patients might be the result of protein leakage from the blood to the CSF attributable to a disrupted blood-brain barrier. To test this hypothesis, we measured the albumin concentration in CSF from brain tumor patients and control patients as well as the blood albumin concentration in brain tumor patients to calculate the CSF/blood albumin ratio, which serves as a good estimate of the integrity of the blood-brain barrier (20 ) .
The median albumin concentration in CSF of brain tumor patients was significantly higher than that in CSF of control patients (0.19 and 0.10 g/L, respectively; P ϭ 0.0001). The median Q alb in brain tumor and control patients were 8.61 ϫ 10 Ϫ3 and 3.04 ϫ 10 Ϫ3 (P Ͻ0.0001), respectively (Fig. 4) , which suggests a disrupted bloodbrain barrier in brain tumor patients, based on the reference Q alb values in children (upper limit for patients under 15 years, 5.0 ϫ 10 Ϫ3 ) (21) (22) (23) . The albumin concentration in CSF was significantly (P Ͻ0.0001) correlated with the peak intensities of the 2 protein peaks in the m/z 17 000 APO A-II protein cluster in our SELDI experiments (Fig. 5) . These data indicate that the increased APO A-II concentration in CSF of brain tumor patients might be explained by a disrupted blood-brain barrier.
Immunohistochemistry did not show specific cellular APO A-II staining in pediatric brain tumor (see supplementary information IV in the online Data Supplement) or healthy cerebellum tissue sections.
Discussion
SELDI ProteinChip technology has been used successfully to compare protein expression profiles in body fluids in various malignancies (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . We analyzed SELDI protein expression profiles of CSF from pediatric brain tumor and control patients and observed 123 protein peak clusters that were differentially expressed with an FDR of 1%. Double-loop classification analysis gave a mean prediction accuracy of 88% and a mean specificity of 88% in discriminating brain tumor patients from control patients. Western blot analysis of CSF from control and brain tumor patients showed differential staining by anti-APO A-II antibody of a protein band at approximately the same mass as the band from which APO A-II was identified by MS/MS (Fig.  2) , confirming the identity of APO A-II. The CSF/blood albumin ratio was calculated in control and brain tumor patients as representation of the integrity of the blood brain barrier. The CSF/blood albumin ratio was significantly higher in brain tumor patients than in control patients, suggesting a disruption of the blood-brain barrier in the brain tumor patients. The lines represent the median value within each subgroup. The CSF albumin concentration was significantly correlated with the peak intensity of both proteins in the M r 17 000 protein cluster observed in the protein expression profiles. f, m/z 17 248 peak (Spearman correlation coefficient ϭ 0.75; P Ͻ0.0001); E, m/z 17 369 peak (Spearman correlation coefficient ϭ 0.91; P Ͻ0.0001).
Probably because of the relatively small number of each brain tumor subtype in our study, we were not able to differentiate between different brain tumor subtypes based on the protein expression profiles of CSF. However, our analysis did identify a protein marker in CSF, which is common to all brain tumors. A protein cluster at m/z 17 000 that was highly discriminative between tumor and control patients was identified as APO A-II by purification and subsequent peptide mass fingerprinting and MS/MS. Western blotting confirmed the identification and differential expression of APO A-II in CSF from brain tumor and control patients.
In most mammals, APO A-II is present in a monomeric form, whereas in humans, APO A-II also exists as a dimer of 2 identical chains, cross-linked by a single disulfide bond at cysteine-6 at the amino terminus of the protein (24, 25 ) . Because the monomeric form of APO A-II is M r 8700, the M r 17 000 form identified in our study most likely represents the dimeric form of APO A-II. The masses of the 2 protein peaks (m/z 17 248 and 17 369) in the m/z 17 000 protein peak cluster in our SELDI spectra were in concordance with previously described masses of isoforms of APO A-II (25, 26 ) . Multiple isoforms of APO A-II have been described in humans (25, (27) (28) (29) and are the result of posttranslational modifications, such as oxidization or truncation of the C-terminal glutamine residue (25) (26) (27) (28) .
APO A-II is the second most abundant human HDL apolipoprotein and is synthesized predominantly in the liver (30 ) . Despite the high abundance of APO A-II, little is known about its biological functions. APO A-II is thought to influence the metabolism of HDL and glucose (31) (32) (33) . Genetic variations in APO A-II appear to be involved in senile amyloidogenesis in mice and humans (30, 34, 35 ) , and APO A-II has recently been linked to malignancies. In contrast to the increased APO A-II concentrations in CSF from brain tumor patients in our study, a study in mice indicated a decrease in serum APO A-II in mice that had received injections of a B-cell lymphoma (36 ) . A study in prostatic disease indicated that a monomeric isoform of APO A-II (M r 8900) is specifically overexpressed in serum of patients with prostate cancer (6 ) .
Our data suggest that the overexpression of APO A-II in CSF from brain tumor patients might have resulted from protein leakage from the blood through a disrupted blood-brain barrier. APO E and APO A-I are the major apolipoproteins in CSF, being present in HDL. Whereas evidence exists that, for example, APO E can be produced by astrocytes and microglia in the central nervous system (37 ) , no data are available that indicate APO A-II production in the central nervous system. In patients with neuroborreliosis, CSF APO A-II concentrations were correlated with albumin concentrations regardless of cytology (38 ) . Because an increased Q alb is indicative of a loss of integrity of the blood-brain barrier, increased APO A-II together with increased CSF albumin might reflect a disrupted blood-brain barrier. The significant difference in CSF albumin concentration between brain tumor patients and control patients, the increased Q alb in brain tumor patients, and the significant correlation between the CSF albumin concentration and the intensity of the APO A-II peak in our SELDI experiments may indicate that a disrupted blood-brain barrier indeed might be the source of the increased APO A-II in CSF of brain tumor patients. Because none of the CSF samples in our study had macroscopic blood contamination, we excluded a traumatic lumbar puncture as the cause of the increased APO A-II in CSF. Additional evidence that the relative abundance of APO A-II in CSF may be attributable to a disrupted blood-brain barrier is our finding of the m/z 17 000 APO A-II cluster in the protein expression profiles of 2 control patients with infected ventriculo-peritoneal drains, in whom ventricular instead of lumbar CSF was analyzed (data not shown).
Malik et al. (6 ) suggested that APO A-II is a potentially specific marker for prostatic disease. Several other apolipoproteins, such as APO D, E, and J, have also been linked to proliferation and cell growth in various malignancies (39 -43 ) , which may suggest that apolipoproteins, including APO A-II, are more general cancer markers, possibly being involved in the regulation of proliferation and growth of tumor cells. However, we observed no specific cellular APO A-II staining in our brain tumor tissue sections. This observation further strengthens the assumption that the increased APO A-II in the CSF of brain tumor patients might be related to a secondary phenomenon, such as a disrupted blood-brain barrier.
In conclusion, our study indicates that SELDI-TOF mass spectrometry can be successfully used to detect proteins that are differentially expressed in CSF of pediatric patients with and without brain tumors. Of the 123 differentially expressed protein peak clusters, we identified a highly overexpressed m/z 17 000 peak cluster in CSF from brain tumor patients as APO A-II. The overexpression of APO A-II in CSF from brain tumor patients was correlated with an increased albumin concentration in CSF, which suggests a relationship with a disrupted blood-brain barrier. Ongoing studies are aimed at detecting subtypespecific proteins in larger groups of pediatric brain tumor patients.
